Bringing you live news and features since 2013
Bringing you news, views and analysis since 2013

35365

CANDRIAM expands health care fund range with launch of Candriam Equities L Life Care

RELATED TOPICS​

 

CANDRIAM, a global multi-asset manager focused on sustainable and responsible investment has picked World Health Day to launch the CANDRIAM Equities L Life Care Fund (the Fund), a sub-fund of the Luxembourg SICAV Candriam Equities L managed by Candriam Luxembourg. 

CANDRIAM, a global multi-asset manager focused on sustainable and responsible investment has picked World Health Day to launch the CANDRIAM Equities L Life Care Fund (the Fund), a sub-fund of the Luxembourg SICAV Candriam Equities L managed by Candriam Luxembourg. 

The Fund invests in a global range of health care sub-sectors including pharmaceuticals & biotechnology, medical technology, and life sciences. The Fund is the latest offering in CANDRIAM’s existing healthcare range, which includes specialist health care strategies, representing over USD4.5 billion in assets under management.
 
Health care is a secular growth theme that benefits from following trends and characteristics:
 

  • Ageing: an ageing population creates a structural demand for all subsectors of the health care industry, as most health care expenditures occur after the age of 60.
  • Innovation: health care innovation never sleeps eg the rise of new technologies,  better drug design, the genomic revolution and robotic assisted surgery
  • Emerging markets: the health care sector is still developing in emerging markets, as access to it and health insurance is continuously improving.
  • Low cyclicality: health care is always a necessity and is thus less dependent of economic conditions.

 
Ageing demographics and economic development are two of the most powerful drivers of health care consumption. The United Nations predicts that by 2050 the global population aged 60-plus will amount to 2.1 billion people, this represents a more than 100 per cent increase from the 1 billion people aged 60-plus in 2017. Furthermore, healthcare spending positively correlates with rising GDP per capita.
 
While the healthcare sector provides a growth opportunity worldwide, Emerging Markets in particular offers an interesting long-term dynamic. China’s per capita healthcare expenditures, having grown at a Compound Annual Growth Rate (CAGR) of eight percent from 2014 through 2018, are forecast to continue rising at a CAGR of seven percent through to 2023. Per capita spending on health care in China stands at only USD647, compared to that of the US which is 17 times greater at USD11,162 per capita. The country’s ageing population coupled with rising wealth will fuel growth in an under-penetrated market.
 
The actively managed Fund uses a fundamental, ‘bottom-up’ approach based on – thorough research and deep understanding of clinical data and the developments in medical technology. The fund managers use a differentiated investment process rooted in over 20 years of biotechnology expertise, allowing them to do in-depth clinical assessment of a drug or technology pipeline.

The investment universe consists of quoted companies that are active in the broad health care space, including pharmaceuticals, biotechnology, life sciences, health care equipment and technology, with a market cap of more than USD250 million. The Fund has no specific regional, style, size or disease bias.
 
The Fund, which is the latest addition to CANDRIAM’s global health care strategy, will be managed by Rudi Van den Eynde, Head of Thematic Global Equity, and Servaas Michielssens, PhD, CFA, both of whom have extensive experience in health care. The fund managers rely on a team of analysts cumulating 28 years of experience in fundamental medical research. Their goal is to ensure the Fund outperforms the MSCI World Net Return benchmark and be well ranked within the peer group of global health care funds. The fund will be registered for distribution in Luxembourg, Austria, Switzerland, Germany, Spain, France, Great Britain, Italy and the Netherlands.
 
Rudi Van den Eynde, Lead Portfolio Manager of the Fund, says: “This is a very exciting time to be launching Candriam Equities L Life Care, especially thanks to the broad progress we see in medical technologies in general. On behalf of our investors, we will strive to identify companies with a high growth potential across the broad health care spectrum. With its in-depth expertise, and 20 years’ experience managing global health care strategies, our team is very well positioned to capitalise on the latest technologies.”
 
Vincent Hamelink, Chief Investment Officer, says: “As ageing demographics, economic development and new innovative treatments will further drive the global health care market growth, our new Candriam Equities L Life Care is designed to offer a unique diversification opportunity for investors.”

Latest News

MSCI has launched MSCI AI Portfolio Insights, writing that it combines generative artificial intelligence “GenAI”..
The Capgemini Research Institute’s World Wealth Report 2024, published today, reveals the number of high-net-worth..
New research from cloud security firm Zscaler reports a disconnect between European company confidence in..

Related Articles

Waves
A joint statement from BNP Paribas Asset Management, Federated Hermes Limited, Mirova, Robeco and Storebrand Asset Management has been published, entitled The urgent need for better ocean-related data to make informed investment decisions...
A joint statement from BNP Paribas Asset Management, Federated Hermes Limited, Mirova, Robeco and Storebrand Asset Management has been published,..
Frozen soap bubble
From the end of this month, the UK’s Sustainability Disclosure Requirements (SDR) regime comes into force which the Financial Conduct Authority says has a simple aim: “Financial products that are marketed as sustainable should do as they claim and have the evidence to back it up.”..
From the end of this month, the UK’s Sustainability Disclosure Requirements (SDR) regime comes into force which the Financial Conduct..
Global ESG Investing
On May 15 Florida’s Republican Governor Ron DeSantis signed legislation that furthers his ongoing campaign to oppose the role of climate change and ESG factors in state policymaking...
On May 15 Florida’s Republican Governor Ron DeSantis signed legislation that furthers his ongoing campaign to oppose the role of..
Trends
The trend to buyout among the UK’s smaller defined benefit (DB) schemes continues with a slew of new sub GBP100 million deals announced this month alone...
The trend to buyout among the UK’s smaller defined benefit (DB) schemes continues with a slew of new sub GBP100..
Subscribe to the Institutional Asset Manager newsletter

Subscribe for access to our weekly newsletter, newsletter archive, updates on the site and exclusive email content.

Marketing by